Cure My Disease

Don't miss your cure!

 Log in / Sign up

Korean study tracks real-world safety of breast cancer drug capivasertib

NCT ID NCT06927648

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This study is a safety check required by Korean health authorities after capivasertib was approved for breast cancer. Researchers will watch for side effects and see how well the drug works in everyday medical practice. About 130 patients in Korea who are already prescribed the drug will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

  • Research Site

    NOT_YET_RECRUITING

    Busan, 34084, South Korea

  • Research Site

    NOT_YET_RECRUITING

    Busan, 49241, South Korea

  • Research Site

    RECRUITING

    Busan, 49267, South Korea

  • Research Site

    NOT_YET_RECRUITING

    Daejeon, 34943, South Korea

  • Research Site

    RECRUITING

    Daejeon, 35015, South Korea

  • Research Site

    RECRUITING

    Goyang-si, 10380, South Korea

  • Research Site

    RECRUITING

    Goyang-si, 10408, South Korea

  • Research Site

    RECRUITING

    Guri-si, 11923, South Korea

  • Research Site

    RECRUITING

    Incheon, 21565, South Korea

  • Research Site

    RECRUITING

    Incheon, 22332, South Korea

  • Research Site

    NOT_YET_RECRUITING

    Seongnam-si, 13620, South Korea

  • Research Site

    RECRUITING

    Seoul, 02841, South Korea

  • Research Site

    RECRUITING

    Seoul, 03722, South Korea

  • Research Site

    NOT_YET_RECRUITING

    Seoul, 06273, South Korea

  • Research Site

    RECRUITING

    Seoul, 06591, South Korea

  • Research Site

    RECRUITING

    Suwon, 16499, South Korea

  • Research Site

    RECRUITING

    Uijeongbu-si, 11765, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.